Apolipoprotein E (ApoE) Genotype Add-On
The ApoE genotype test identifies which combination of the ε2, ε3, and ε4 alleles a patient carries. ApoE isoforms modulate LDL cholesterol, dietary fat responsiveness, and Alzheimer disease risk; ε4 carriage raises cardiovascular and neurodegenerative risk, while homozygous ε2 is the genetic prerequisite for type III hyperlipoproteinaemia.
1
Biomarkers
Blood (whole blood)
Sample
7–10 business days
Turnaround
No
Fasting
What is the ApoE Genotype test?
The Apolipoprotein E (ApoE) Genotype Add-On determines which combination of the three common APOE alleles a patient carries, information that modulates cardiovascular and neurodegenerative risk stratification and can guide lipid management. ApoE is not a first-line diagnostic test—its result is a risk modifier, not a diagnosis—and it is ordered as an adjunct when the practitioner judges that genotype data will refine treatment intensity, inform dietary advice, or help interpret a lipid phenotype that does not fit the usual pattern. Because ApoE4 carriage raises LDL cholesterol, increases dietary saturated-fat responsiveness, and confers higher Alzheimer risk, some practitioners genotype patients with strong family histories, refractory dyslipidaemia, or early cognitive symptoms to sharpen risk estimates and optimise non-pharmacological interventions. Conversely, homozygous ApoE2 is the genetic prerequisite for type III hyperlipoproteinaemia, and genotyping confirms that diagnosis in patients with elevated triglycerides, remnant cholesterol, and tuberoeruptive xanthomata. The test is always interpretive, never screening, and informed consent regarding the implications—particularly for Alzheimer risk—is essential before ordering.
What does the ApoE Genotype test measure?
Apolipoprotein E is a polymorphic glycoprotein synthesised predominantly in the liver and brain that mediates receptor-mediated endocytosis of lipoproteins through binding the LDL receptor and LDL receptor-related protein. The three common isoforms—E2, E3, and E4—differ by single amino-acid substitutions that alter receptor affinity and lipoprotein clearance. The ε4 allele is associated with higher LDL cholesterol, reduced cholesterol efflux, and impaired neuronal lipid homeostasis; the ε2 allele with lower LDL but increased triglyceride-rich remnants and, in homozygous form, dysbetalipoproteinaemia.
ApoE genotype influences lipid metabolism, cardiovascular risk, and Alzheimer disease susceptibility. Carriers of ε4 exhibit higher baseline LDL cholesterol, greater dietary fat responsiveness, and a dose-dependent increase in Alzheimer risk; ε4/ε4 homozygotes carry a substantially higher lifetime risk than ε3/ε3 individuals. The ε2 allele confers modest cardioprotection through lower LDL but, in ε2/ε2 homozygotes, can unmask type III hyperlipoproteinaemia when a metabolic insult is present. Genotyping informs therapeutic lipid targets, dietary modification, and—where clinicians and patients judge the information useful—risk stratification for cognitive decline.
Why is the ApoE Genotype test ordered?
- Investigation of suspected type III hyperlipoproteinaemia (dysbetalipoproteinaemia) in patients with elevated triglycerides, remnant cholesterol, and palmar or tuberoeruptive xanthomata
- Refractory or unexplained dyslipidaemia, particularly when LDL response to dietary or pharmacological therapy is atypical or when precision lipid management is considered
- Strong family history of premature cardiovascular disease, where genotype may refine risk assessment and justify more aggressive lipid targets
- Patients with early cognitive impairment or strong family history of Alzheimer disease, when the practitioner and patient agree that genotype information will inform lifestyle modification, monitoring intensity, or research trial eligibility
- Personalisation of dietary advice, recognising that ε4 carriers may benefit more from reduced saturated fat and the Mediterranean dietary pattern than non-carriers
- Research or precision-medicine contexts where lipoprotein metabolism or neurodegeneration pathways are under study
Sample collection and turnaround
Sample type
Blood (whole blood)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
7–10 business days
Collection notes
Phlebotomy at a draw site approved for Boston Heart Diagnostics routing; DNA is extracted from peripheral leukocytes in EDTA whole blood. Genotype is stable, so timing relative to meals, medications, or lipid-lowering therapy is irrelevant. Avoid testing shortly after transfusion or transplant.
Specimen requirements
EDTA whole blood (lavender-top tube), minimum 3 mL. DNA is stable at room temperature for several days and refrigerated or frozen for long-term storage. Confirm specimen identity to prevent sample swap.
What can affect ApoE Genotype results?
Genotype is fixed at conception; a discordant result on repeat testing signals a pre-analytical error rather than biological change, so specimen identity must be assured.
Circulating donor leukocytes can produce a mixed or donor genotype; delay genotyping until the patient's own haematopoiesis is re-established, or use buccal cells.
The assay targets the three common alleles (ε2, ε3, ε4); rare variants may be misclassified or require Sanger sequencing confirmation if the clinical picture does not fit.
ε4 frequency varies by ancestry (higher in populations of African and Oceanic descent), so population context informs prior probability but does not alter individual interpretation.
Knowledge of ε4 carriage, particularly homozygosity, can cause anxiety or alter health behaviours; informed consent and, where appropriate, genetic counselling should precede testing.
What do ApoE Genotype results mean?
Elevated
Not applicable—results are genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4), not quantitative elevations. Each diplotype confers a distinct lipid and neurological risk profile.
Normal
ε3/ε3 is the most common and ancestral genotype, associated with average lipid levels and Alzheimer risk. ε2 carriage (ε2/ε3, ε2/ε2) lowers LDL cholesterol modestly but raises remnant lipoproteins; ε2/ε2 homozygotes are at risk of type III hyperlipoproteinaemia when a secondary metabolic trigger (obesity, diabetes, hypothyroidism) is present. ε4 carriage (ε3/ε4, ε4/ε4) raises LDL cholesterol, increases dietary saturated-fat responsiveness, and confers a dose-dependent elevation in Alzheimer risk—ε4/ε4 homozygotes have substantially higher lifetime risk than ε3/ε3 individuals but the majority do not develop dementia, so genotype is not deterministic.
Reduced
Not applicable—results are categorical genotypes, not continuous measurements.
Note: ApoE genotype is a risk modifier, not a diagnostic test for cardiovascular disease or Alzheimer disease. Lipid phenotype and cognitive outcomes are polygenic and heavily modified by environment, so genotype informs but does not dictate management. Because the result has implications for neurodegenerative risk, informed consent and discussion of the psychological and insurability consequences should occur before ordering. Genetic privacy, data security, and potential discrimination are considerations in jurisdictions without robust genetic-information protection. Type III hyperlipoproteinaemia requires homozygous ε2 plus a metabolic trigger; ε2 carriage alone does not cause the phenotype.
Frequently asked questions
The three common alleles—ε2, ε3, and ε4—differ by single amino-acid substitutions that alter receptor binding. ε3 is ancestral and most common; ε4 binds LDL receptors avidly, raising LDL cholesterol and Alzheimer risk; ε2 binds poorly, lowering LDL but increasing remnant lipoproteins.
How to access the ApoE Genotype test
The ApoE Genotype reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. (2000)
- Eichner JE, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. (2002)
- Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. (2011)
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. (2019)
- Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer's disease: progress to date and the path forward. Neuron. (2019)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.